Wed, Jul 23, 2014, 7:53 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Myriad Genetics Inc. Message Board

  • moosedogger moosedogger Mar 4, 2000 9:29 AM Flag

    OT bigeasy- re CLL run-it's new to me

    but here's what i see from the
    website-

    they have a reasonably strong claim to be in the
    genomics business-

    i'm just guessing, but that's
    why i bought it-

    your view would be
    appreciated since you have obviously taken the time to
    understand the company (i haven't)

    thanks in advance

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Re: Myriad Genetics, Inc. -
      Registration
      Statement on Form S-3 (Registration No. 333-31734)



      Dear Ladies and Gentlemen:
      Pursuant to Rule 477(a)
      promulgated under the Securities Act of 1933, as amended,
      Myriad Genetics, Inc. (the "Registrant") hereby
      respectfully requests that the Securities and Exchange
      Commission consent to the withdrawal of its Registration
      Statement on Form S-3 (Registration No. 333-31734),
      together with all exhibits and amendments thereto (the
      "Registration Statement"). The Registrant is requesting such
      withdrawal because of unfavorable market conditions that
      would adversely affect the offering of the shares of
      common stock, par value $.01 per share, covered by the
      Registration Statement.

      The Registrant further
      requests that, pursuant to Rule 477(c), an order with the
      date of the granting of the withdrawal be included in
      the file for the above-captioned Registration
      Statement in the following manner: "Withdrawn upon the
      request of the Registrant, the Commission consenting
      thereto."

      Please address any questions you may have
      to Edward P. Gonzales, Esquire, at Mintz, Levin,
      Cohn, Ferris, Glovsky and Popeo, P.C., One Financial
      Center, Boston, Massachusetts 02111, telephone number
      (617) 542-6000, facsimile number
      (617) 542-2241.


      Thank you for your assistance with this matter.


      http://www.nasdaq.com/asp/quotes_sec.asp?

      symbol=MYGN%60&selected=MYGN%60

    • Well, I came looking for more information on
      Celltech and why the run of late. Is it not odd that I am
      the one providing the information now?

      Medeva
      information from before the merger showed a great pipeline
      company that was faltering on execution. They had a joint
      venture go bad with Abbott back in 1998, and they have a
      plant burndown (or explode) in 1999. So they had a
      great pipeline, but no way to produce thier patented
      stuff. They were also paying larege dividends about once
      every three or four quarters.

      Along comes the
      merger to create Celltech. I was seriously considering
      dumping my shares at that time since it was not clear if
      they were going to have SEC approval to trade the new
      stock as ADRs, but they would be seeking. I was nervous
      that I would have a stock that I could not trade. Well
      I decided to ride it out, and I am glad that I
      did.

      Okay now for some future stuff:
      From reading the
      merger notes, you will find that they have formed the
      largest biotech company in the EU with strong
      distribution in the US. This is great since they have a great
      pipeline with the aging baby boomers. They stand to have a
      very bright future.

 
MYGN
37.63+0.46(+1.24%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.